NIH Budget and Funding Outlook 2026: What Researchers Should Know

NIH Budget Overview: Where the Money Comes From

The National Institutes of Health is funded through the annual federal appropriations process, primarily through the Labor, Health and Human Services, Education, and Related Agencies (Labor-HHS) appropriations bill. NIH is part of the Department of Health and Human Services (HHS), and its budget is a discretionary spending line item, meaning Congress must approve it each year.

NIH's budget has two major components. The largest is extramural research, which accounts for approximately 80-83% of total spending. This is the money that flows to universities, medical schools, research institutes, and other external organizations through grants and contracts. The remainder funds intramural research (conducted at NIH's own laboratories, primarily on the Bethesda, Maryland campus), research management and support, and construction.

For extramural researchers, the key figure is the amount available for Research Project Grants (RPGs), which includes R01s, R21s, R03s, and related mechanisms. In FY2023, NIH obligated approximately $27.1 billion for extramural research, with roughly $13.3 billion going to RPGs. The total number of RPG awards was approximately 30,000, supporting research at over 2,500 institutions across all 50 states.

Understanding this structure matters because when people refer to "the NIH budget," the total number (approximately $47.3 billion in FY2023 including supplemental funding) includes many components beyond the grants that directly affect your lab. The RPG pool is what most directly determines whether your application gets funded.

Historical NIH Budget Trends (2015-2026)

The NIH budget has been on a complex trajectory over the past decade. After the sequestration cuts of 2013, which reduced NIH funding to approximately $29.2 billion, Congress began a sustained period of bipartisan increases that lasted through FY2023.

The period from FY2015 to FY2023 represented a historically favorable era for NIH. Total funding grew by approximately $17 billion, or about 56%, over that span. However, when adjusted for biomedical research inflation (BRDPI), the real purchasing power increase was more modest, roughly 25-30%, because the cost of conducting research has risen significantly. Reagent costs, personnel salaries, and equipment prices all grew during this period.

The FY2024 budget marked a turning point. While the nominal budget was essentially flat, it represented a real decrease in purchasing power when accounting for inflation. For FY2025 and FY2026, the outlook is more uncertain, with various proposals suggesting flat funding, modest cuts, or in some scenarios, more significant reductions. The political environment, broader federal spending debates, and agency restructuring discussions all contribute to this uncertainty.

How the Budget Gets Allocated Across Institutes

NIH comprises 27 institutes and centers (ICs), each with its own budget, scientific mission, and funding priorities. The largest institutes by budget have historically been the National Cancer Institute (NCI, approximately $7.3 billion in FY2023), the National Institute of Allergy and Infectious Diseases (NIAID, approximately $6.3 billion), and the National Heart, Lung, and Blood Institute (NHLBI, approximately $3.8 billion). Smaller institutes like the National Institute on Deafness and Other Communication Disorders (NIDCD, approximately $500 million) or the National Institute of Nursing Research (NINR, approximately $180 million) operate with vastly smaller budgets.

Budget allocation across institutes is partly historical and partly driven by Congressional directives. Congress sometimes earmarks funds for specific disease areas or mandates minimum spending on particular research topics. The NIH Director has some flexibility to move funds between institutes, but the institute-level budget structure means that funding tightness varies significantly across scientific domains. A researcher studying cancer may face different payline dynamics than one studying kidney disease.

Each institute sets its own payline, which is the percentile score below which applications are generally funded. In FY2024, paylines ranged from approximately 10th percentile (at some smaller or more constrained institutes) to the low 20s (at larger or better-funded institutes). NCI, for example, typically funds R01s at around the 11th-13th percentile, while NIGMS has historically maintained paylines around the 21st-23rd percentile. These differences mean that the same application scoring the 15th percentile might be funded at one institute but not another.

Impact on Grant Success Rates

The overall NIH success rate for Research Project Grants has fluctuated over the past two decades. In the early 2000s, following the NIH doubling (which concluded in FY2003), the RPG success rate was approximately 30-32%. By FY2013, following sequestration, it had fallen to roughly 16.8%, a historic low. The recovery in funding from FY2015 onward brought the success rate back up to approximately 20-23% by FY2023.

If the budget flattens or declines in real terms, success rates will likely decrease again. The mechanism is straightforward: a flat budget supports fewer new and competing renewal grants because existing multi-year commitments must be honored first. NIH has ongoing obligations to fund the out-years of previously awarded multi-year grants. When the budget does not grow, the pool available for new awards shrinks, even if the total budget appears stable.

Application volume also matters. The number of R01-equivalent applications submitted to NIH has been relatively stable at approximately 55,000-58,000 per year in recent cycles. If applications remain steady while the budget contracts, the mathematical result is lower success rates. Some estimates suggest that a 5% real budget reduction could push overall RPG success rates below 18%, approaching the post-sequestration low.

Current Policy Landscape and Its Effects on Researchers

Beyond the budget numbers, several policy-level factors are affecting the research funding environment in 2026. Federal agency restructuring discussions, changes in research priorities, evolving policies around indirect cost rates, and increased scrutiny of foreign influence in federally funded research all create operational complexity for principal investigators and institutions.

The indirect cost rate debate is particularly consequential. Indirect costs, also called facilities and administrative (F&A) costs, are the overhead payments NIH makes to institutions to cover the costs of supporting research, including building maintenance, research administration, libraries, and utilities. Negotiated rates vary widely, from approximately 40% at some institutions to over 60% at major research universities. Proposals to cap or reduce indirect cost rates would effectively reduce the total dollars flowing to research institutions, potentially affecting infrastructure, staffing, and the institutional support that makes NIH-funded research possible.

For individual investigators, the practical impact of these policy discussions includes uncertainty about award timing, potential changes to allowable costs, and evolving compliance requirements. Research security requirements related to foreign collaborations and reporting obligations have also increased, adding administrative burden to grant management.

What Budget Changes Mean for Different Career Stages

How to Adapt Your Funding Strategy

In an uncertain budget environment, the most resilient researchers are those who diversify their funding, submit their strongest possible applications, and maintain flexibility in their research programs. Here are concrete steps to strengthen your position.

Submit fewer, stronger applications rather than many weak ones. When paylines are tight, the marginal application that you rush to submit is unlikely to succeed and consumes time you could spend improving your strongest submission. A well-crafted R01 that scores in the 15th percentile has a realistic chance at many institutes; a hasty submission that scores in the 30th percentile does not.

Leverage the resubmission strategically. NIH allows one resubmission (A1) of an unfunded application. Resubmitted applications that thoughtfully address reviewer concerns historically have higher success rates than new submissions. Treat the summary statement as a detailed roadmap for improvement. Address every significant criticism and make it easy for reviewers to see what changed.

Talk to program officers before and after submission. Program officers have insight into funding priorities, upcoming FOAs, and whether your project fits their institute's portfolio. A pre-submission conversation can help you target the right institute and mechanism. A post-review conversation can clarify whether resubmission is advisable or whether pivoting to a different mechanism or institute would be more productive.

Consider collaborative and multi-PI mechanisms. In tight budget environments, NIH often maintains or increases support for collaborative, team science, and center grants (U01, P01, P20) because these represent efficient use of funds across multiple investigators. Being part of a collaborative application can provide funding even when single-PI grants are harder to obtain.

Build bridge funding relationships at your institution. Many universities offer internal bridge funding, pilot grants, or startup extensions for investigators between external awards. Knowing what is available at your institution and applying proactively, before a funding gap occurs, can maintain your lab's operations during a competitive renewal period.

Diversifying Beyond NIH: Alternative Federal and Private Funding

While NIH is the dominant funder of biomedical research, it is not the only source, and budget uncertainty makes diversification more important than ever. Several other federal agencies and private organizations fund research that overlaps with NIH's mission.

• NSF (National Science Foundation): Funds basic research in biology, engineering, and computational sciences. The BIO directorate supports fundamental biological research, while CBET supports bioengineering. NSF budgets are subject to the same appropriations dynamics as NIH but are often considered separately by Congress. Total NSF budget is approximately $9-10 billion.
• DOD (Department of Defense): The Congressionally Directed Medical Research Programs (CDMRP) fund research in breast cancer, prostate cancer, traumatic brain injury, and many other areas. CDMRP awards are often substantial ($500K-$3M) and have different review criteria than NIH. The DOD Peer Reviewed Medical Research Program is open to a wide range of health topics.
• ARPA-H: The Advanced Research Projects Agency for Health, established in 2022, funds high-risk, high-reward health research with a focus on translational and breakthrough technologies. With an initial budget of approximately $1.5 billion, ARPA-H represents a new and growing funding source with a different operational model than traditional NIH grants.
• Private foundations: The American Cancer Society, American Heart Association, Alzheimer's Association, March of Dimes, and hundreds of smaller disease-focused foundations collectively provide billions in research funding. Success rates and award sizes vary, but these grants often have faster review timelines and different eligibility criteria than NIH.
• Industry partnerships: Sponsored research agreements, CRADAs (Cooperative Research and Development Agreements), and SBIR/STTR partnerships provide alternative funding streams that can complement NIH support.

A diversified portfolio does not mean spreading yourself thin. It means identifying 2-3 funding sources beyond NIH that are genuinely good fits for your research program and maintaining active applications at each. This reduces the impact of any single funder's budget fluctuations on your lab.

Using This Site's Tools to Track Funding Shifts

Budget changes do not affect all research areas equally. Some topics receive increased priority even in flat budgets, while others lose relative share. Our tools help you see these shifts in real time.

Use Grant Trends to search for your research keywords and see how funding volume has changed over recent years. If your area shows declining award counts, it may signal tighter paylines at the relevant institute, which should inform your application timing and mechanism choice. Conversely, a research area showing growth may indicate new or expanded funding opportunities.

The PI Finder tool shows which investigators have recently received new awards, giving you a window into what NIH is currently prioritizing. If multiple new R01s are being awarded on a topic closely related to your work, it suggests active interest from reviewers and program staff. The Weekly Updates provide the most current data on recently approved grants across all institutes.

For researchers considering which institute to target, our NIH Funding Success Rates by Topic analysis provides context on how different research areas perform across institutes. In a constrained budget, choosing the right institute and study section can be the difference between a fundable and unfundable score.